文献速递妇科肿瘤

顺铂吉西他滨新辅助化疗后放化疗对比单纯放化疗治疗局部晚期宫颈癌:随机II期试验

Neoadjuvant Chemotherapy With Cisplatin and Gemcitabine Followed by Chemoradiation Versus Chemoradiation for Locally Advanced Cervical Cancer: A Randomized Phase II Trial.
PubMed 文献 · J Clin Oncol · 2019-08-26

该II期随机试验纳入107例局部晚期宫颈癌患者,比较顺铂+吉西他滨新辅助化疗(NAC)三周期后标准放化疗与单纯标准放化疗的疗效。结论提示在标准放化疗前加用该NAC方案不优于、甚至可能劣于单纯放化疗。

要点

  • 顺铂吉西他滨NAC后放化疗较单纯放化疗显著降低3年PFS和OS
  • NAC组完全缓解率显著低于单纯放化疗组
  • 该NAC方案不推荐用于局部晚期宫颈癌的常规治疗

核心结论

  • 在局部晚期宫颈癌中,顺铂+吉西他滨新辅助化疗后标准放化疗不优于、甚至可能劣于单纯标准放化疗。

研究设计与样本

  • II期随机试验,纳入107例局部晚期宫颈癌患者(FIGO IIB-IVA期或淋巴结阳性),随机分为NAC联合放化疗组55例和单纯放化疗组52例。
  • NAC方案为顺铂+吉西他滨三周期,随后行每周顺铂+盆腔放疗的标准放化疗;主要终点为3年无进展生存率。

主要发现

  • 两组毒性相似,但NAC组低镁血症和神经病变更常见。
  • 多数患者为鳞状细胞癌(87.8%)。

临床怎么用

  • 局部晚期宫颈癌的标准治疗仍为含顺铂的放化疗,不应在放化疗前常规加用顺铂+吉西他滨新辅助化疗。

局限性

  • II期试验样本量较小(107例),结论需更大规模III期试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Although chemoradiation therapy (CRT) with cisplatin remains the standard treatment of patients with locally advanced cervical cancer (LACC), 40% of patients present with disease recurrence. Additional treatment strategies are required to improve outcomes. We conducted a trial to evaluate the efficacy and safety of neoadjuvant chemotherapy (NAC) with cisplatin and gemcitabine followed by CRT. METHODS: In this phase II trial, patients with LACC (International Federation of Gynecology and Obstetrics stage IIB to IVA or with positive lymph nodes) were randomly assigned to three cycles of NAC with cisplatin and gemcitabine followed by standard CRT with weekly cisplatin plus pelvic radiotherapy or to standard CRT alone. The primary end point was 3-year progression-free survival (PFS). Secondary end points were response rate, 3-year locoregional control, 3-year overall survival (OS), safety, and quality of life. RESULTS: From 107 patients enrolled in the trial, 55 were randomly assigned to the NAC arm and 52 to the CRT-alone arm. The majority of patients had squamous cell carcinoma (87.8%). After a median follow-up of 31.7 months, NAC was associated with an inferior PFS, with 3-year PFS rates of 40.9% v 60.4% in the CRT arm (hazard ratio, 1.84; 95% CI, 1.04 to 3.26; P = .033). NAC also was associated with a lower OS (3-year OS rate, 60.7% v 86.8%; hazard ratio, 2.79; 95% CI, 1.29 to 6.01; P = .006). After treatment completion, complete response rates were 56.3% in the NAC arm and 80.3% in the CRT arm (P = .008). Toxicities were similar in both arms, with the exception of hypomagnesemia and neuropathy being more common with NAC. CONCLUSION: This study shows that the addition of NAC consisting of cisplatin and gemcitabine to standard CRT is not superior and is possibly inferior to CRT alone for the treatment of LACC.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. da Costa SCS, Bonadio RC, Gabrielli FCG, et al. Neoadjuvant Chemotherapy With Cisplatin and Gemcitabine Followed by Chemoradiation Versus Chemoradiation for Locally Advanced Cervical Cancer: A Randomized Phase II Trial. J Clin Oncol. 2019. PMID: 31449470. doi:10.1200/JCO.19.00674

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。